Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedotin has significant clinical activity in patients with relapsed or refractory cHL and relapsed or refractory ALCL, and has the potential to represent a significant advance in modern oncology.
INTRODUCTION
CD30 is a prosurvival receptor, which belongs to the tumor necrosis factor receptor (TNFR) superfamily [1] . Although CD30 was recognized in the early 1980s as an important marker for Hodgkin Reed-Sternberg cells (HRS), it is now known that CD30 is also expressed in other B cell and T cell non-Hodgkin's lymphomas (NHL), as well as in a normal subset of activated B-and T-natural killer (NK) cells and activated monocytes [2] .
Two lymphoid neoplasms are characterized by strong and uniform expression of CD30: Hodgkin's lymphomas (HL) and anaplastic large cell lymphoma (ALCL). HL accounts for approximately 11% of all malignant lymphomas, and is further classified in two major subtypes: classical (cHL) and nodular lymphocyte predominant HL [3] . In cHL, modern treatment combining chemotherapy and radiotherapy can cure the majority of patients. However, 10-30% of patients may progress or relapse, depending on baseline risk factors and type of treatment [4] . Up to 50% of these patients can still be cured with high-dose chemotherapy and autologous stem cell transplantation (ASCT). The prognosis of patients who are primary refractory or relapse after ASCT is poor, with a median overall survival (OS) of approximately 2 years, constituting a highly unmet medical need [5] .
Systemic chemotherapy. However, patients with ALKnegative ALCL tend to have low response rates and up to 60% of patients may relapse after front-line therapy [6] . High-dose therapy and ASCT may result in long-term remission in 30-40% of patients with chemosensitive disease [7] .
FIRST GENERATION ANTI-CD30 ANTIBODIES
Rituximab, an anti-CD20 monoclonal antibody (mAb), has consistently proved to increase the response rates and disease-free survival in almost all B cell neoplasms [8] . [12] .
MDX-060 is a fully human anti-CD30 immunoglobulin G1j mAb with greater antibody-dependent, cell-mediated cytotoxicity.
In a sequential phase 1/2 study, 72 patients with HL (n = 63), ALCL (n = 7), and CD30? T cell lymphoma (n = 2) were enrolled. MDX-060 was well tolerated, with no MTD identified. However, limited single-agent activity was observed, with only 6 patients with clinical responses and 25 patients with stable disease [13] . The second generation anti-CD30 antibodies (MDX-1401 and XmAb2513) have modified Fc (fragment, crystallizable) regions to increase efficacy. Preliminary results from phase 2 studies show good tolerability but limited efficacy [14, 15] .
BRENTUXIMAB VEDOTIN
Since minimal activity was observed in trials of first-generation ''naked'' anti-CD30 antibodies, and the combination of SGN-30 with cytotoxic agents resulted in significant toxicity, new strategies for immunotherapy against CD30
were tested including the development of an antibody-drug conjugate (ADC).
The combination of the chimeric anti-CD30
antibody cAC10 with monomethylauristatin E (MMAE), a potent antimitotic agent, led to the development of brentuximab vedotin [16] . A protease-cleavable linker was used to attach MMAE to cAC10, offering significant stability, with less than 2% release of the drug from the mAb after 10-day incubation in human plasma [17] . Brentuximab vedotin has a well defined structure with an average of four drugs per mAb and no free MMAE in the drug product. relative to the unconjugated antibody [18] . In vivo studies in animals suggest that only a fraction of MMAE released from the ADC is metabolized, mainly via oxidation by CYP3A4/ 5. The elimination of MMAE occurs both in urine and feces, the latter being responsible for 72% of the total MMAE recovered. Interestingly, the elimination of MMAE appears to be limited by its rate of release from the ADC. There are currently no studies on dose adjustment for special populations, such as elderly patients, or patients with renal or hepatic impairment. Furthermore, 81% of patients with B symptoms had resolution of symptoms following treatment, regardless of response status. For patients receiving the MTD, the ORR was 50%.
CLINICAL STUDIES IN CD30? MALIGNANCIES
In another phase 1 study [20] , 44 patients with relapsed/refractory CD30? malignancies Over 70% of patients had primary refractory disease and 42% had disease refractory to the most recent therapy, with a median number of prior therapies of 3.5 (range, 1-13) excluding ASCT. The ORR was 75%, and 34% of all patients achieved a CR. Furthermore, tumor reductions were observed in nearly all patients (94%). The median duration of response was 6.7 months, and was longer (20.5 months) for patients who achieved a CR. The estimated 12-month overall survival was 89% and the estimated median progression-free survival (PFS) was 5.6 months, although patients achieving a CR had considerably longer (21.7 months) PFS. As observed in the phase 1 studies, the most common adverse events were peripheral sensory neuropathy (42%), nausea (35%), fatigue (34%), neutropenia (19%), diarrhea (18%), pyrexia (14%), vomiting (13%), arthralgia (12%), pruritus (12%), myalgia (11%), peripheral motor neuropathy (11%), and alopecia (10%). PN was the most common adverse effect leading to treatment discontinuation. However, complete resolution of all events of peripheral neuropathy was observed in 50% of the patients [21] .
In Complete resolution of symptoms occurred in 48% of patients and the median time to improvement or resolution was 9.9 weeks. For patients who develop grade 2 or 3 neuropathy, it is recommended that treatment be withheld until neuropathy improves to grade 1, and the dose should then be decreased to 1.2 mg/kg.
Since severe pulmonary toxicity was observed in the phase 1/2 study of SGN-30 combined with gemcitabine, vinorelbine, and lyposomal doxorubicin, there was a concern that pulmonary toxicity could be observed with there is a possible genetic cause, since distinct FCcRIIa and FCcRIIIa polymorphisms was observed in these patients [12] .
Since the approval of brentuximab vedotin, two confirmed cases and one suspected case of progressive multifocal leukoencephalopathy (PML) were reported [24] , and patients with new-onset central nervous system abnormalities should be evaluated promptly. Due to the serious nature of PML a new ''Boxed Warning'' highlighting this potential risk was added to the drug label [25] . PML has been observed with the use of other mAbs, especially with rituximab. Although with the latter, a possible B cell depletion and consequent immunosuppression can play a causative role, it is known that activated B-and T cells express CD30, and an anti-CD30 therapy can possibly lead to dysregulation of the immune system.
CURRENT STUDIES AND FUTURE DIRECTIONS
Based on the encouraging results from phase 2 studies, brentuximab vedotin is currently being investigated in different disease settings. Given the high response rate in the relapsed setting and the manageable toxicity profile, incorporating brentuximab vedotin into firstline therapy represents an attractive option.
Ansell et al. [23] recently presented the interim results of a phase 1 study of brentuximab vedotin combined with ABVD or AVD (doxorubicin, vinblastine, dacarbazine) in patients with newly diagnosed advanced-stage cHL. In total, 47 patients were evaluated after treatment, and only 7 patients had to discontinue therapy due to adverse events.
Bleomycin was discontinued in 11 patients due to pulmonary toxicity, and all other adverse events were mild and manageable. The objective response was 96%, with 21 of 22 patients in the ABVD and 23 of 25 patients in the AVD group achieving a CR.
Multiple studies are being conducted with brentuximab in different scenarios. A phase 3 trial of brentuximab vedotin combined with AVD versus ABVD is being planned. In addition, a phase 3 placebo-controlled trial is evaluating the efficacy of brentuximab vedotin given as maintenance therapy in high-risk patients after
ASCT. An estimated 322 patients completed accrual and will receive best supportive care following ASCT plus either brentuximab vedotin 1.8 mg/kg every 3 weeks, or placebo.
Gopal et al. [26] recently showed that brentuximab vedotin is safe in patients relapsing after allogeneic SCT, with clinical responses in 50% of patients, and modest adverse events.
Brentuximab vedotin is also being tested in other CD30? nonlymphomatous malignancies [27] , T/NK lymphomas [28] and in steroidrefractory graft versus host disease [29] .
DISCUSSION
The introduction of a safe and effective anti-CD30 ADC has written another chapter in one of the most successful histories in modern oncology. HL, previously a lethal disease, is now highly curable when treated with multiagent chemotherapy regimens, with or without radiation therapy. For those patients not responding to first-line therapy, high-dose chemotherapy followed by ASCT can cure almost 50% of patients [5] . However, a fraction of patients will not benefit from this strategy, in particular patients with primary refractory or chemoresistant disease, and those not eligible for ASCT.
The challenge in making a successful history more successful has led to intense research in cHL, especially in the relapse/refractory setting.
Moreover, the fact that conventional chemotherapy may fail to eradicate the disease, and that the interaction between HRS and the surrounding stroma may play a major role, have brought new targets to attention. Histone deacetylase inhibitors [30] , mammalian target of rapamycin inhibitors [31] , and immunomodulatory agents [32] Furthermore, the response rates observed with brentuximab vedotin are superior to other novel single agents [30] [31] [32] .
The prognosis of patients with sALCL treated with conventional therapy is relatively poor, especially if the disease is ALK-negative. For these patients, the benefit of ASCT as salvage therapy is even more subtle, and patients not achieving a CR or at least a good PR before ASCT usually have poor prognosis. Moreover, patients failing ASCT have few options. New drugs have received accelerated approvals from the FDA for treatment of relapsed/refractory peripheral T cell lymphoma, including ALCL. However, in phase 2 trials that preceded the approval of these drugs (pralatrexate and romidepsin), the ORR rates were less than 30%, with less than 15% of patients achieving a CR [34, 35] .
Thus, the options for ALCL patients failing first-line treatment are even scarcer, with inferior outcomes. Therefore, brentuximab vedotin has proven the best option for those patients, even before ASCT, especially when less than a CR is achieved by salvage therapy. For those patients, brentuximab vedotin is a rational bridge before transplant.
Finally, the next step when treating cHL and ALCL patients in CR after treatment with brentuximab vedotin is unclear. Although allogeneic transplant is possible, retreatment may also be possible. In a case series, patients with CD30? malignancies underwent retreatment, and objective responses were observed in six of eight patients [36] .
CONCLUSION
Brentuximab vedotin is an anti-CD30 ADC with proven efficacy in patients with relapsed or refractory HL and relapsed or refractory sALCL. 
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